Stanford Cancer Institute Breakthroughs in Cancer: John Heymach, MD, PhD
Stanford Cancer Institute
732 views
Title: Beyond Driver Oncogenes: New Paradigms for Personalizing
Lung Cancer Therapies
Date: 02.10.2026
As a physician-scientist, Dr. Heymach’s research focuses on investigating mechanisms of therapeutic resistance to targeted agents, understanding the regulation of angiogenesis in lung cancer, and the development of biomarkers for targeted agents and immunotherapy. His research has led to new therapeutic approaches for KRAS mutant lung cancer, small cell lung cancer (SCLC), EGFR mutant non-small cell lung cancer (NSCLC), adenoid cystic carcinoma, and oligometastatic NSCLC, many of which are now considered standard-of-care regimens or undergoing clinical testing.
Speaker Intro: 00:12
Talk: 3:15
Audience Q&A: 51:35
Learn more about our Breakthroughs in Cancer seminar series: https://med.stanford.edu/cancer/about...
Learn more about the Stanford Cancer Institute: https://med.stanford.edu/cancer
Follow the Stanford Cancer Institute
LinkedIn: LinkedIn: stanford-cancer
X: Twitter: SCIDirector
X: Twitter: StanfordCancer
Instagram: Instagram: stanford.cancer
Subscribe to the Stanford Cancer Institute: @stanfordcancerinstitute
#LungCancer #Oncology #Stanford
Stanford Cancer Institute Breakthroughs in Cancer: John Heymach, MD, PhD
Stanford Cancer Institute
732 views
Title: Beyond Driver Oncogenes: New Paradigms for Personalizing
Lung Cancer Therapies
Date: 02.10.2026
As a physician-scientist, Dr. Heymach’s research focuses on investigating mechanisms of therapeutic resistance to targeted agents, understanding the regulation of angiogenesis in lung cancer, and the development of biomarkers for targeted agents and immunotherapy. His research has led to new therapeutic approaches for KRAS mutant lung cancer, small cell lung cancer (SCLC), EGFR mutant non-small cell lung cancer (NSCLC), adenoid cystic carcinoma, and oligometastatic NSCLC, many of which are now considered standard-of-care regimens or undergoing clinical testing.
Speaker Intro: 00:12
Talk: 3:15
Audience Q&A: 51:35
Learn more about our Breakthroughs in Cancer seminar series: https://med.stanford.edu/cancer/about...
Learn more about the Stanford Cancer Institute: https://med.stanford.edu/cancer
Follow the Stanford Cancer Institute
LinkedIn: LinkedIn: stanford-cancer
X: Twitter: SCIDirector
X: Twitter: StanfordCancer
Instagram: Instagram: stanford.cancer
Subscribe to the Stanford Cancer Institute: @stanfordcancerinstitute
#LungCancer #Oncology #Stanford